NCT00352898View on ClinicalTrials.gov

Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™

PHASE2CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

April 30, 2006

Study Completion Date

November 30, 2006

Conditions
MumpsRubellaMeaslesVaricella
Interventions
BIOLOGICAL

MeMuRu-OKA (study vac)

BIOLOGICAL

MMR, Varicella vacc (control)

Trial Locations (6)

94015

GSK Investigational Site, Enna

95027

GSK Investigational Site, San Gregorio Di Catania (CT)

97100

GSK Investigational Site, Ragusa

T5N 4A3

GSK Investigational Site, Edmonton

V6H 3N1

GSK Investigational Site, Vancouver

B3K 6R8

GSK Investigational Site, Halifax

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00352898 - Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™ | Biotech Hunter | Biotech Hunter